Impact of molecular processing in the hinge region of therapeutic IgG4 antibodies on disposition profiles in cynomolgus monkeys
K Stubenrauch, U Wessels, JT Regula… - Drug Metabolism and …, 2010 - ASPET
The IgG4 isotype antibody is a potential candidate for immunotherapy when reduced effector
functions are desirable. However, antigen binding fragment (Fab) arm exchange leads to …
functions are desirable. However, antigen binding fragment (Fab) arm exchange leads to …
[HTML][HTML] Crystal structure of an anti-Ang2 CrossFab demonstrates complete structural and functional integrity of the variable domain
…, J Moelleken, JT Regula, W Schaefer, M Thomas… - PLoS …, 2013 - journals.plos.org
Bispecific antibodies are considered as a promising class of future biotherapeutic molecules.
They comprise binding specificities for two different antigens, which may provide additive …
They comprise binding specificities for two different antigens, which may provide additive …
Variable heavy–variable light domain and Fab-arm CrossMabs with charged residue exchanges to enforce correct light chain assembly
JT Regula, S Imhof-Jung, M Mølhøj… - Protein Engineering …, 2018 - academic.oup.com
Technologies for the production of bispecific antibodies need to overcome two major
challenges. The first one is correct heavy chain assembly, which was solved by knobs-into-holes …
challenges. The first one is correct heavy chain assembly, which was solved by knobs-into-holes …
Dual inhibition of Ang-2 and VEGF via a novel human bispecific bivalent IgG1 CrossMAb shows potent anti-angiogenic, antitumoral, and antimetastatic efficacy and …
M Thomas, Y Kienast, W Scheuer, E Lorenzon… - Cancer research, 2012 - AACR
VEGF-A blockade has been extensively clinically validated as a treatment for human cancers.
Angiopoietin-2 (Ang-2) expression has been shown to function as a key regulator of blood …
Angiopoietin-2 (Ang-2) expression has been shown to function as a key regulator of blood …
[HTML][HTML] What is the biologically relevant KD for VEGF binding to ranibizumab in the eye? A comparison of in-vivo and in-vitro estimates.
…, J Moelleken, C Gassner, JT Regula - … & Visual Science, 2016 - iovs.arvojournals.org
Purpose: The high affinity binding of anti-VEGF antibodies to VEGF molecules within the
eye is central to their mechanism of action in the treatment of neovascular and vascular …
eye is central to their mechanism of action in the treatment of neovascular and vascular …
A Human Neutralizing Antibody Specific to Ang‐2 Inhibits Ocular Angiogenesis
ES Rennel, JT Regula, SJ Harper, M Thomas… - …, 2011 - Wiley Online Library
Please cite this paper as: Rennel, Regula, Harper, Thomas, Klein and Bates (2011). A Human
Neutralizing Antibody Specific to Ang‐2 Inhibits Ocular Angiogenesis. Microcirculation 18(…
Neutralizing Antibody Specific to Ang‐2 Inhibits Ocular Angiogenesis. Microcirculation 18(…
[HTML][HTML] Engineering therapeutic bispecific antibodies using CrossMab technology
C Klein, W Schaefer, JT Regula, C Dumontet… - Methods, 2019 - Elsevier
Bispecific antibodies have recently gained major interest as they allow novel mechanisms-of-action
and/or therapeutic applications that cannot be achieved using conventional IgG-…
and/or therapeutic applications that cannot be achieved using conventional IgG-…
[HTML][HTML] Anti-Angiogenic Activity of a Tetravalent Bispecific Antibody (TAvi6) Targeting VEGF and Angiopoietin-2
KM Weidner, W Scheuer, M Thomas, M Baehner… - Blood, 2010 - Elsevier
Abstract 4304 Background: VEGF blockade has been validated clinically as a treatment for
human cancers. Angiopoietin-2 (Ang-2) expression has been shown to function as a key …
human cancers. Angiopoietin-2 (Ang-2) expression has been shown to function as a key …
Improved methods for profiling glycosylation of proteins
G Pohlentz, K Neue, A Zeck, JT Regula… - … 年大会 (JHUPO 第 9 回 …, 2011 - jstage.jst.go.jp
The carbohydrate part of glycoproteins is involved in a variety of functions including the
proper folding and the quality control of newly synthesized glycoproteins in the endoplasmic …
proper folding and the quality control of newly synthesized glycoproteins in the endoplasmic …
Abstract B86: Ang-2-VEGF-A CrossMab, a novel bispecific human IgG1 antibody blocking VEGF-A and Ang-2 functions simultaneously, mediates potent antitumor …
…, S Yu, HH The, L Martarello, C Klein, M Thomas - Cancer Research, 2013 - AACR
Purpose: VEGF-A blockade has been validated clinically as a treatment for human cancers.
Angiopoietin-2 (Ang-2) expression has been shown to function as a key regulator of tumor …
Angiopoietin-2 (Ang-2) expression has been shown to function as a key regulator of tumor …